Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 Jul;98(7):1058–1061.

Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.

Fadil Akyol 1, Ugur Selek 1, Gokhan Ozyigit 1, Cem Onal 1, Bulent Akdogan 1, Erdem Karabulut 1, Haluk Ozen 1
PMCID: PMC2569461  PMID: 16895273

Abstract

OBJECTIVES: To prospectively assess the efficacy and tolerability of bicalutamide monotherapy on biochemical failure of localized prostate cancer following total androgen deprivation (TAD) and 3D-conformal radiotherapy (3D-CRT). METHODS: Between January 1998 and January 2002, we prospectively evaluated 20 eligible patients with biochemical failure. All patients were initially treated with neoadjuvant TAD of 12 weeks before 3D-CRT (73.6 Gy at isocenter) and same regimen of TAD after completion of radiotherapy for 24 weeks in high-risk patients. We prescribed 150 mg/day bicalutamide monotherapy for 24 weeks in patients with biochemical failure according to American Society for Therapeutic Radiology and Oncology 1997 consensus definition. Primary end points were biochemical control (BC) and metastasis-free survival (MFS). RESULTS: Median follow-up was 28 months after biochemical failure date. At last visit, the median PSA level of all patients was 2.80 ng/dl while 1.28 ng/dl for nonmetastatic and 30.7 ng/dl for metastatic patients. BC was successfully obtained in five of them with only bicalutamide. Ten patients developed distant metastasis among 15 patients receiving salvage TAD. MFS was 55% at three years for all 20 patients. Temporary gynecomasty was observed in 11 patients as the only serious toxicity. CONCLUSIONS: Bicalutamide monotherapy seems to be a tolerable regimen for patients with biochemical failure following 3D-CRT, and TAD and may be effective in patients with low PSA levels at biochemical failure.

Full text

PDF
1058

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akyol Fadil, Ozyigit Gokhan, Selek Ugur, Karabulut Erdem. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone. Eur Urol. 2005 Apr 18;48(1):40–45. doi: 10.1016/j.eururo.2005.04.007. [DOI] [PubMed] [Google Scholar]
  2. Andriole G., Lieber M., Smith J., Soloway M., Schroeder F., Kadmon D., DeKernion J., Rajfer J., Boake R., Crawford D. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995 Mar;45(3):491–497. doi: 10.1016/s0090-4295(99)80021-1. [DOI] [PubMed] [Google Scholar]
  3. Bales G. T., Chodak G. W. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996 Jan;47(1A):38–53. doi: 10.1016/s0090-4295(96)80007-0. [DOI] [PubMed] [Google Scholar]
  4. Bouchot O., Lenormand L., Karam G., Prunet D., Gaschignard N., Malinovsky J. M., Buzelin J. M. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol. 2000 Nov;38(5):543–549. doi: 10.1159/000020353. [DOI] [PubMed] [Google Scholar]
  5. Bruchovsky N., Rennie P. S., Coldman A. J., Goldenberg S. L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990 Apr 15;50(8):2275–2282. [PubMed] [Google Scholar]
  6. Brufsky A., Fontaine-Rothe P., Berlane K., Rieker P., Jiroutek M., Kaplan I., Kaufman D., Kantoff P. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 1997 Jun;49(6):913–920. doi: 10.1016/s0090-4295(97)00091-5. [DOI] [PubMed] [Google Scholar]
  7. Crook J. M., Szumacher E., Malone S., Huan S., Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology. 1999 Mar;53(3):530–534. doi: 10.1016/s0090-4295(98)00547-0. [DOI] [PubMed] [Google Scholar]
  8. De La Taille A., Zerbib M., Conquy S., Amsellem-Ouazana D., Thiounn N., Flam T. A., Debré B. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 2003 Jan;91(1):18–22. doi: 10.1046/j.1464-410x.2003.04015.x. [DOI] [PubMed] [Google Scholar]
  9. Fleshner N. E., Fair W. R. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 1996 Dec;78(6):907–910. doi: 10.1046/j.1464-410x.1996.29918.x. [DOI] [PubMed] [Google Scholar]
  10. Fleshner N. E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. 1995 Nov;154(5):1642–1646. [PubMed] [Google Scholar]
  11. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up. Mol Urol. 1999;3(3):287–292. [PubMed] [Google Scholar]
  12. Grossfeld G. D., Small E. J., Lubeck D. P., Latini D., Broering J. M., Carroll P. R. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug;58(2 Suppl 1):56–64. doi: 10.1016/s0090-4295(01)01243-2. [DOI] [PubMed] [Google Scholar]
  13. Higano C. S., Ellis W., Russell K., Lange P. H. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996 Nov;48(5):800–804. doi: 10.1016/S0090-4295(96)00381-0. [DOI] [PubMed] [Google Scholar]
  14. Iversen P., Tyrrell C. J., Kaisary A. V., Anderson J. B., Van Poppel H., Tammela T. L., Chamberlain M., Carroll K., Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol. 2000 Nov;164(5):1579–1582. [PubMed] [Google Scholar]
  15. Jhaveri F. M., Zippe C. D., Klein E. A., Kupelian P. A. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999 Nov;54(5):884–890. doi: 10.1016/s0090-4295(99)00252-6. [DOI] [PubMed] [Google Scholar]
  16. Kaisary A. V., Iversen P., Tyrrell C. J., Carroll K., Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer Prostatic Dis. 2001;4(4):196–203. doi: 10.1038/sj.pcan.4500531. [DOI] [PubMed] [Google Scholar]
  17. Ornstein D. K., Rao G. S., Johnson B., Charlton E. T., Andriole G. L. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology. 1996 Dec;48(6):901–905. doi: 10.1016/s0090-4295(96)00315-9. [DOI] [PubMed] [Google Scholar]
  18. Partin A. W., Pearson J. D., Landis P. K., Carter H. B., Pound C. R., Clemens J. Q., Epstein J. I., Walsh P. C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994 May;43(5):649–659. doi: 10.1016/0090-4295(94)90180-5. [DOI] [PubMed] [Google Scholar]
  19. Patel A., Dorey F., Franklin J., deKernion J. B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997 Oct;158(4):1441–1445. doi: 10.1016/s0022-5347(01)64238-1. [DOI] [PubMed] [Google Scholar]
  20. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591–1597. doi: 10.1001/jama.281.17.1591. [DOI] [PubMed] [Google Scholar]
  21. Sandhu S. S., Matveev V. B., Kaisary A. V. Finasteride plus flutamide for prostatic carcinoma. Br J Urol. 1997 Aug;80(2):360–360. [PubMed] [Google Scholar]
  22. Tyrrell C. J., Kaisary A. V., Iversen P., Anderson J. B., Baert L., Tammela T., Chamberlain M., Webster A., Blackledge G. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33(5):447–456. doi: 10.1159/000019634. [DOI] [PubMed] [Google Scholar]
  23. Verhelst J., Denis L., Van Vliet P., Van Poppel H., Braeckman J., Van Cangh P., Mattelaer J., D'Hulster D., Mahler C. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994 Oct;41(4):525–530. doi: 10.1111/j.1365-2265.1994.tb02585.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES